Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-rhG-CSF versus daily rhG-CSF during neoadjuvant FLOT for advanced gastric cancer
ChiCTR-IIR-17012923Phase 3Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pegfilgrastim and filgrastim in gastric cancer (GC) (2 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Neutrophil descent time. Started Dec 2017; status: recruiting.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-IIR-17012923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012923.